Amsterdam UMC

Amsterdam 32 trials 10 recruiting

32 Registered trials

10 Currently recruiting

Organisation

Amsterdam UMC

Location

Amsterdam, Netherlands

Identifier

ORG-100031899

Address

Meibergdreef 9, 1105 AZ, Netherlands

Departments

Cardiology
Department Infectious deseases
Department of Ophthalmology
Hematology
infectious diseases
Internal Medicine
Medical Oncology
Neurology
Oncology
Paediatric Nephrology
pediatric nephrology
pediatric neurology

Clinical trials at this site (32)

Search interface

An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised

2022-501463-40-00 Locally Advanced or Metastatic Cholangiocarcinoma 5
A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi… Not authorised

2022-502099-22-00 HIV-1 Infection 5
Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Not authorised

2022-502968-20-01 Idiopathic Inflammatory Myopathies 4
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting

2022-500367-12-00 Dermatomyositis 5 2022-11-30
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the… Recruiting

2022-501677-39-00 Adolescent Renal Allografts 5 2021-05-25
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma Recruiting

2022-501811-14-00 Multiple Myeloma 9 2024-09-20
Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Recruiting

2022-502968-20-02 Behcet's disease 4 2024-05-30
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 neuroendocrine tumours 6 2023-06-28
The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ… Recruiting

2022-501620-26-00 prosthetic joint infection 6 2023-05-15
WOEST-3 Recruiting

2022-502140-13-00 Atrial fibrillation Acute coronary syndrome Chronic cor 6 2023-01-11
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting

2023-503267-42-00 Patients with a histological diagnosis of mismatch- rep 5 2022-06-10
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended

2022-502808-72-00 Chronic Lymphocytic Leukemia 4 2024-09-11
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Or… Ended

2022-501438-46-00 Retinitis Pigmentosa 5 2024-01-22
HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation… Ended

2022-502225-17-00 Hodgkin lymphoma 4 2023-07-14
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended

2022-501463-40-01 Locally Advanced or Metastatic Cholangiocarcinoma 5 2023-05-03
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended

2022-502664-21-00 multiple sclerosis 6 2023-05-01
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff… Ended

2022-501076-26-00 high risk diffuse large B-cell lymphoma 4 2018-08-28
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d… Ended

2022-501038-48-00 Diffuse Large B-Cell Lymphoma 4 2018-07-26
European randomised clinical trial on mPOX Infection (EPOXI) Ended

2022-501979-10-00 Monkeypox 6 2024-08-08